drugset / Trial / NCT07309900
IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies
Phase 1
Recruiting
12 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Shanghai IASO Biotechnology Co., Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an investigator-initiated, single-arm, open-label clinical study. It employs a dose-escalation design to evaluate the safety, pharmacokinetics, and preliminary efficacy of IASO208 injection in relapsed/refractory B-cell malignancies.
Timeline
- Start
- 2025-11-21
- Primary completion
- 2028-12-15
- Completion
- 2029-06-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IASO208 | Unknown | 1e+08 unknown | — |
| Subject | IASO208 | Unknown | 3e+08 unknown | — |
| Subject | IASO208 | Unknown | 6e+08 unknown | — |
| Subject | IASO208 | Unknown | 9e+08 unknown | — |
| Subject | IASO208 | Unknown | 1.2e+09 unknown | — |
| Subject | IASO208 | Unknown | 1.5e+09 unknown | — |
| Subject | IASO208 | Unknown | 1.8e+09 unknown | — |